匹配无关供者造血细胞移植中标准移植物抗宿主病预防联合或不联合抗人T淋巴细胞免疫球蛋白的长期结局:随机对照试验最终结果
该随机对照试验最终随访8.6年,比较环孢素联合甲氨蝶呤加或不加抗人T淋巴细胞免疫球蛋白(ATLG)预防移植物抗宿主病(GvHD)的长期结局。ATLG组广泛型慢性GvHD发生率显著降低(14% vs 52%,校正HR 0.18),无严重GvHD且无复发生存率显著提高(34% vs 13%,校正HR 0.55),且停用免疫抑制治疗的概率更高(47% vs 11%)。
要点
- ATLG组8年广泛型慢性GvHD发生率为14%,非ATLG组为52%(校正HR 0.18,95%CI 0.09-0.34;p<0.0001)。
- ATLG组8年无严重GvHD且无复发生存率为34%,非ATLG组为13%(校正HR 0.55,95%CI 0.39-0.76;p=0.0003)。
- ATLG组8年存活且停用免疫抑制治疗的概率为47%,非ATLG组为11%。
核心结论
- 在标准环孢素联合甲氨蝶呤预防方案中加入ATLG可长期改善无严重GvHD且无复发生存。
- 在清髓性预处理后的无关供者移植中,使用ATLG大幅提高存活且停用免疫抑制治疗的概率,从而降低长期免疫抑制相关风险。
研究设计与样本
- 随机对照试验最终长期随访分析,2003年5月26日至2007年2月8日入组202例血液恶性肿瘤患者,中心分层区组随机分配。
- 201例接受清髓性预处理后外周血(n=164;82%)或骨髓(n=37;18%)移植的患者纳入全分析集,按随机分组分析(ATLG组n=103,非ATLG组n=98)。
- 中位随访8.6年(IQR 8.0-9.3);慢性GvHD分析仅纳入100天时存活且未二次移植的患者(ATLG组90例,非ATLG组80例)。
主要发现
- 8年时广泛型慢性GvHD发生率ATLG组14%(95%CI 8-29)vs 非ATLG组52%(95%CI 42-64),校正HR 0.18(95%CI 0.09-0.34;p<0.0001)。
- 8年非复发死亡率ATLG组21%(95%CI 14-30)vs 非ATLG组34%(95%CI 26-45),校正HR 0.66(95%CI 0.38-1.16;p=0.15),未达统计学显著。
- 8年复发率ATLG组35%(95%CI 27-46)vs 非ATLG组30%(95%CI 22-41),校正HR 1.17(95%CI 0.71-1.93;p=0.54);复发死亡率ATLG组31%(95%CI 23-41)vs 非ATLG组29%(95%CI 21-40),校正HR 1.03(95%CI 0.61-1.76;p=0.90)。
- 8年无病生存率ATLG组44%(95%CI 35-54)vs 非ATLG组36%(95%CI 27-46),校正HR 0.91(95%CI 0.63-1.31;p=0.60);总生存率ATLG组49%(95%CI 39-59)vs 非ATLG组37%(95%CI 27-47),校正HR 0.82(95%CI 0.56-1.20;p=0.31)。
- 8年无严重GvHD且无复发生存率ATLG组34%(95%CI 25-43)vs 非ATLG组13%(95%CI 7-21),校正HR 0.55(95%CI 0.39-0.76;p=0.0003)。
临床怎么用
- 作者认为,在标准环孢素联合甲氨蝶呤预防方案中加入ATLG可长期改善无严重GvHD且无复发生存。
- 作者认为,在清髓性预处理后的无关供者移植中使用ATLG大幅提高存活且停用免疫抑制治疗的概率,从而降低长期免疫抑制相关风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previously, we demonstrated that the addition of anti-human-T-lymphocyte immunoglobulin (ATLG) to standard ciclosporin and methotrexate prophylaxis reduced graft-versus-host disease (GvHD) in adult patients treated with allogeneic haemopoietic cell transplantation from matched unrelated donors without negatively affecting relapse and survival. Since reports on long-term results from randomised trials testing anti-thymocyte globulin are scarce, we performed an extended follow-up of the trial. METHODS: Between May 26, 2003, and Feb 8, 2007, 202 patients with haematological malignancies were centrally randomly assigned using computer-generated centre-stratified block randomisation to receive ciclosporin and methotrexate with or without ATLG. 201 patients who underwent transplantation with peripheral blood (n=164; 82%) or bone marrow (n=37; 18%) grafts after myeloablative conditioning were included in the full analysis set, and were analysed according to their randomly assigned treatment (ATLG n=103, non-ATLG n=98). We assessced chronic GvHD, non-relapse mortality, relapse, relapse mortality, disease-free survival, overall survival, severe GvHD-free (acute GvHD III-IV, and extensive chronic GvHD) and relapse-free survival, and time under immunosuppressive therapy after long-term follow-up. The trial is registered with the German Clinical Trials Register (DRKS00000002), ClinicalTrials.gov (NCT00655343), and EudraCT (2004-000232-91). FINDINGS: Median follow-up was 8·6 years (IQR 8·0-9·3). Only patients at risk for chronic GvHD (ie, patients who were alive and without a second transplant at 100 days) were included in the analyses of chronic GvHD (90 patients in the ATLG group, 80 patients in the non-ATLG group). At 8 years, the incidence of extensive chronic GvHD was 14% (95% CI 8-29) in the ATLG group versus 52% (42-64) in the non-ATLG group (adjusted hazard ratio [HR] 0·18, 95% CI 0·09-0·34; p<0·0001). Non-relapse mortality was 21% (95% CI 14-30) versus 34% (26-45; adjusted HR 0·66, 95% CI 0·38-1·16; p=0·15), incidence of relapse was 35% (95% CI 27-46) versus 30% (22-41; adjusted HR 1·17, 95% CI 0·71-1·93; p=0·54), relapse mortality was 31% (95% CI 23-41) versus 29% (21-40; adjusted HR 1·03, 95% CI 0·61-1·76; p=0·90), disease-free survival was 44% (95% CI 35-54) versus 36% (27-46) (adjusted HR 0·91, 95% CI 0·63-1·31; p=0·60), overall survival was 49% (95% CI 39-59) versus 37% (27-47; adjusted HR 0·82, 95% CI 0·56-1·20; p=0·31), and severe GvHD-free and relapse-free survival was 34% (25-43) versus 13% (7-21) (adjusted HR 0·55, 95% CI 0·39-0·76; p=0·0003). The probability of being alive and free of immunosuppressive therapy was 47% (95% 37-57) in the ATLG group and 11% (5-18) in the non-ATLG group at 8 years. INTERPRETATION: ATLG in addition to standard ciclosporin and methotrexate as GvHD prophylaxis improves severe GvHD-free and relapse-free survival in the long term. The use of ATLG in unrelated donor transplantation after myeloablative conditioning substantially increases the probability of surviving free of immunosuppressive therapy, and thus reduces the risk associated with long-term immunosuppression. FUNDING: Neovii Biotech.
引用
- Finke J, Schmoor C, Bethge WA, et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol. 2017. PMID: 28583289. doi:10.1016/S2352-3026(17)30081-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。